AKT1 and metabolic dysfunction-associated steatohepatitis: The latest research showed that AdipoRs dual agonist JT003 could improve metabolic dysfunction-associated steatohepatitis (MASH) and related liver fibrosis through the AMPK, PPARα, and PI3K-Akt signaling pathways, so AdipoRs agonists may be a candidate drug for the development of effective treatments for MASH and related fibrosis (Xu et al. 2020).